Abstract Number: 1345 • 2014 ACR/ARHP Annual Meeting
Improving Pneumococcal Immunization Rates for Patients on Immunosuppressant Medications at an Academic Rheumatology Clinic
Background/Purpose: Patients with rheumatologic diseases are frequently placed on immunosuppressant medications which increase their risk of developing Streptococcus pneumoniae infections. The Advisory Committee on Immunization…Abstract Number: 1344 • 2014 ACR/ARHP Annual Meeting
Electronic Medical Record-Based Best Practice Alert Used By Clinical Staff Improved Pneumococcal Vaccination and Documentation Among Immunosuppressed Rheumatoid Arthritis Patients
Background/Purpose: The Centers for Disease Control and American College of Rheumatology guidelines recommend pneumococcal vaccination for all immunosuppressed patients, specifically those taking disease modifying antirheumatic…Abstract Number: 1343 • 2014 ACR/ARHP Annual Meeting
A Quality Improvement Initiative to Improve Pneumococcal Vaccination Rates in Immunosuppressed Patients
Background/Purpose Patients with autoimmune diseases are at increased risk of complicated infections, and immunomodulating treatment regimens further enhance this risk. Many of these infections,…Abstract Number: 1342 • 2014 ACR/ARHP Annual Meeting
Improving Serologic Testing for Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus
Background/Purpose: Antiphospholipid antibodies (APL) in patients with Systemic Lupus Erythematosus (SLE) are common. Persistent positivity is known to increase the risk of thrombosis and pregnancy…Abstract Number: 1361 • 2014 ACR/ARHP Annual Meeting
Rheumatologists’ Attitudes on Cardiovascular Risk and Lipid Screening in Patients with Rheumatoid Arthritis at an Academic Medical Center
Background/Purpose: Cardiovascular (CV) disease is a major cause of morbidity and mortality in the rheumatoid arthritis (RA) population. Thus, the recognition and management of cardiovascular…Abstract Number: 1360 • 2014 ACR/ARHP Annual Meeting
Monitoring Methotrexate and Leflunomide Treatment for Liver Toxicity: the Kaiser Permanente Experience
Background/Purpose: Methotrexate (MTX) and Leflunomide (LEF) are widely prescribed to treat rheumatologic and other diseases. Each has the potential to cause liver injury in some…Abstract Number: 1358 • 2014 ACR/ARHP Annual Meeting
A Systematic Analysis of the Safety of Prescribing Anti-Rheumatic Immunosuppressive and Biologic Drugs in Pregnant Women
Background/Purpose The use of anti-rheumatic drugs in pregnancy is often complicated by concerns over their potential for adverse effects. Given that rheumatic diseases often affect…Abstract Number: 1359 • 2014 ACR/ARHP Annual Meeting
Care of Women with Rheumatological Conditions during Family Planning and Pregnancy
Background/Purpose Rheumatological diseases often affect women of reproductive age and can impact pregnancy outcomes. There is a need to understand how patients (pts) are managed…Abstract Number: 1329 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical and Serological Features of Childhood Sjögren Syndrome Based on the Presence or Absence of Parotitis
Background/Purpose: Sjögren syndrome is a complex autoimmune disease that affects lacrimal and salivary glands with the potential to cause damage to other organs. Diagnosis of…Abstract Number: 1328 • 2014 ACR/ARHP Annual Meeting
Modulation of Natural IgM-Autoantibodies to Oxidative Stress-Related Neo-Epitopes on Apoptotic Cells in Newborns of Mothers with Anti-Ro Autoimmunity
Background/Purpose At birth, the human immune system expresses substantial circulating levels of polymeric IgM that include autoantibodies to oxidation-associated epitopes on apoptotic cells. This study…Abstract Number: 1327 • 2014 ACR/ARHP Annual Meeting
Decreased CD3-CD16CD56+ Natural Killer Cell Counts Are Associated with Disease Activity in Children with Orbital Myositis
Background/Purpose: Orbital myositis (OM), an inflammatory disease affecting the extra-ocular muscles, typically presents in the third decade. It more commonly affects females and is extremely…Abstract Number: 1326 • 2014 ACR/ARHP Annual Meeting
Transition of Care and Long-Term Outcomes of Juvenile Systemic Sclerosis during Adulthood: Results from a French Single-Center Case-Control Study
Background/Purpose To describe the transition of care from Pediatric to an adult Internal Medicine department and long-term outcomes of patients with juvenile-onset SSc. Methods Twenty…Abstract Number: 1325 • 2014 ACR/ARHP Annual Meeting
Single Hub and Access Point for Pediatric Rheumatology in Europe (SHARE): Evidence Based Recommendations for Diagnosis and Treatment of Juvenile Localized Scleroderma and Juvenile Systemic Sclerosis
Background/Purpose Juvenile Localized Scleroderma (JLS) and Juvenile Systemic Sclerosis (JSSc) form a group of rare pediatric diseases that can lead to significant morbidity. Evidence-based guidelines…Abstract Number: 1324 • 2014 ACR/ARHP Annual Meeting
Predictors of Disease Relapse in Juvenile Localized Scleroderma
Background/Purpose Localized scleroderma (LS) is an autoimmune disease characterized by inflammation of the skin and underlying tissue leading tissue damage including atrophy, dyspigmentation, and fibrosis. …Abstract Number: 1323 • 2014 ACR/ARHP Annual Meeting
Gastrointestinal Involvement in Juvenile Systemic Sclerosis: Development of Recommendations for Screening and Investigation
Background/Purpose There are currently no agreed recommendations on how to investigate children for gastrointestinal (GI) involvement in Juvenile Systemic Sclerosis (JSSc). The aim of screening…
ACR Meeting Abstracts